Latest news
Jazz Pharmaceuticals Raises Guidance on Q2 Earnings Strength - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 00:50:00 GMTLurbinectedin Second-Line SCLC Indication to Be Withdrawn After LAGOON - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 14:09:27 GMTRecon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca - RAPSRAPS · Tue, 04 Aug 2026 20:19:00 GMTJAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View - TradingViewTradingView · Tue, 04 Aug 2026 17:42:00 GMTJazz to withdraw Zepzelca with FDA in second-line small cell lung cancer - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 13:18:16 GMTJazz Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Mon, 03 Aug 2026 22:03:49 GMT